Cargando…

Association between tumor (18)F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer

We examined whether (18)F-fluorodeoxyglucose metabolism is associated with distant relapse-free survival (DRFS) and overall survival (OS) in women with estrogen receptor (ER)-positive, HER2-negative breast cancer. This was a cohort study examining the risk factors for survival that had occurred at t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chae, Sun Young, Park, Seol Hoon, Lee, Hyo Sang, Ahn, Jin-Hee, Kim, Sung-Bae, Jung, Kyung Hae, Kim, Jeong Eun, Ahn, Sei Hyun, Son, Byung Ho, Lee, Jong Won, Ko, Beom Seok, Kim, Hee Jeong, Gong, Gyungyub, Oh, Jungsu S., Park, Seo Young, Moon, Dae Hyuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098458/ https://www.ncbi.nlm.nih.gov/pubmed/35552460 http://dx.doi.org/10.1038/s41598-022-11603-z

Ejemplares similares

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2014)

The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer
por: Song, In Hye, et al.
Publicado: (2022)

Comparison of diagnostic sensitivity of [(18)F]fluoroestradiol and [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer
por: Chae, Sun Young, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling
por: Lee, Hee Jin, et al.
Publicado: (2016)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment
por: Chae, Heejung, et al.
Publicado: (2018)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

Breast-conserving surgery with 3D-printed surgical guide: a single-center, prospective clinical study
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
por: Yoo, Changhoon, et al.
Publicado: (2012)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
por: Lee, Hee Jin, et al.
Publicado: (2015)

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
por: Kwak, Youngji, et al.
Publicado: (2023)

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007)

Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution’s experience
por: Alqudaihi, Heba Mohammad Abdulla, et al.
Publicado: (2022)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023)

No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery
por: Yoon, Tae In, et al.
Publicado: (2018)

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Lee, Hee Jin, et al.
Publicado: (2013)

Prognostic Factors for Distant Metastasis in Patients with Locoregional Recurrence after Mastectomy
por: Jeong, Yuri, et al.
Publicado: (2015)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
por: Lee, So Jeong, et al.
Publicado: (2017)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
por: Shin, Junyoung, et al.
Publicado: (2023)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

Recurrence of Breast Carcinoma as Paget's Disease of the Skin along the Core Needle Biopsy Tract after Skin-Sparing Mastectomy
por: Choi, Soojeong, et al.
Publicado: (2020)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Prediction Model for Tumor Budding Status Using the Radiomic Features of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Cervical Cancer
por: Chong, Gun Oh, et al.
Publicado: (2021)

Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Treatment results of breast cancer patients with locoregional recurrence after mastectomy
por: Jeong, Yuri, et al.
Publicado: (2013)

Diagnostic and prognostic value of preoperative (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography
por: Lee, Joo Young, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_arb7n2u91lslkmbl4plpke0143